News
Can You Trust Your Financial Advisor?
There is a disconnect in the financial industry, and it is yet to be resolved.The problem is that too many people who work as financial advisors aren't legally required to have their clients' best
3 High-Yield ETFs for Retirees
Income is the lifeblood of retirement, but by definition, once you quit working, your income will be coming from new sources -- like your portfolio. To cover your needs, you could regularly sell some
The 3 Stocks on the MFM Team's Radar This Week
In this Motley Fool Money podcast segment, host Chris Hill asks Million Dollar Portfolio's Jason Moser and Matt Argersinger, and Total Income's Ron Gross to tell us about the companies they have their
Canadian Solar's Second Quarter Disappointed on Every Level
The second quarter of 2017 will likely prove to have been a high point for Chinese solar manufacturers, which made it a key for Canadian Solar (NASDAQ: CSIQ). In results released Monday before the
If You Could Place Only 1 Bet on "The Next Big Thing"...
In this Motley Fool Money podcast segment, host Chris Hill, Million Dollar Portfolio's Jason Moser and Matt Argersinger, and Total Income's Ron Gross ponder an interesting hypothetical question from a
2 Attractive Dividend Stocks Whose Dividends Could Double
One of the best reasons to love dividends stocks is that many of them not only pay regular dividends, but also consistently increase their dividend payouts. This results in a nice stream of growing
One Company That's Set to Win From Precision Medicine
In the last few decades, incredible strides have been made in genome typing and precision medicine technology. What used to cost hundreds of thousands of dollars is now available for $100, opening up
How Snap Inc.'s Management Made a Bad Quarterly Report Worse
In this Motley Fool Money podcast segment, host Chris Hill, Million Dollar Portfolio's Jason Moser and Matt Argersinger, and Total Income's Ron Gross consider the business model problems of Snap Inc.
Wayfair Got Punished for Its Same Old Story; Blue Apron Keeps Singing the Blues
In this Motley Fool Money podcast segment, host Chris Hill, Million Dollar Portfolio's Jason Moser and Matt Argersinger, and Total Income's Ron Gross try to explain why the market seemed to lose some
Snap, Inc. Shares Rise on Analyst Upgrade
Just yesterday, Cantor Fitzgerald dropped its price target on Snap (NYSE: SNAP) from $17 to $15 while maintaining its overall neutral rating on the Snapchat operator's shares. The reduction was
This Company Is One of the Safest Plays on the Marijuana Industry
The marijuana industry in the U.S. is huge and growing at an exponential rate, but between regulations and legal uncertainty, the industry is incredibly risky for businesses and investors. Luckily for
O2i : Croissance interne soutenue au 1er semestre 2017 : +12%
Croissance interne soutenue au 1er semestre 2017 : +12%
Amélioration des marges
Confirmation des perspectives de croissance
_________________________________________
T2 2016
T2....
What Happened in the Stock Market Today
After enjoying the biggest single-day gains of the summer on Monday, stocks waffled between positive and negative territory for most of Tuesday's trading. When all was said and done, the Dow Jones
2 Very Different Market Reactions to Priceline and TripAdvisor's Strong Quarters
In this Motley Fool Money podcast segment, host Chris Hill, Million Dollar Portfolio's Jason Moser, and Total Income's Ron Gross discuss the online travel agencies' earnings results, which were solid
Problems With Investing in the Marijuana Industry Today
The marijuana industry is quite large in the U.S. today, and it might be on track to grow at an exponential rate -- but the key word there is "might." Marijuana producers and dispensaries face an
Blue Apron's Failed Execution Just Opened the Door for the Competition
Blue Apron (NYSE: APRN) reported disappointing earnings results last week. While its revenue came in above expectations, it reported a bigger loss per share than most were hoping for.But that's not
Why Coach, Windstream Holdings, and YY Slumped Today
Tuesday was relatively calm on Wall Street, with major benchmarks finishing with mixed results but staying close to where they began the day. Absent big market-shifting news, a lot of individual
Why Disney Had to Launch Streaming Services
In this Motley Fool Money podcast segment, host Chris Hill, Million Dollar Portfolio's Jason Moser and Matt Argersinger, and Total Income's Ron Gross dig into the revelations from Bob Iger about his
Why Shares of Photronics Tumbled Today
Shares of photomask manufacturer Photronics (NASDAQ: PLAB) slumped on Tuesday following the company's third-quarter results and news that the CFO was retiring. Photronics missed analyst estimates for
Why Wynn Resorts, Extreme Networks, and Calumet Specialty Products Partners Jumped Today
Major benchmarks didn't make any big moves on Tuesday, as market participants largely turned their attention toward the latest maneuverings among Wall Street's institutional investors. Quarterly
Why Westport Fuel Systems Inc.'s Shares Popped 15% Today
Shares of natural gas technology company Westport Fuel Systems Inc. (NASDAQ: WPRT) jumped as much as 15.2% in trading Tuesday, after the company posted second-quarter earnings. A year after it merged
How Shopify Inc. Makes Most of Its Money
Investors in Shopify (NYSE: SHOP) have seen their stock double in 2017 alone and triple in two short years on the public market. That's an undeniably awesome return on your investment, but how does
Why Gilead Sciences Might Not Make an Oncology Acquisition
Is Gilead Sciences (NASDAQ: GILD) backing away from its plans to acquire a smaller biotech focusing on oncology? That could be the case. Gilead CEO John Milligan reportedly told Leerink analyst
So This Is Why Facebook Wanted WhatsApp So Badly
I've long been a skeptic of Facebook's (NASDAQ: FB) massive WhatsApp acquisition, mostly because I still think the social network overpaid, which in turn creates significant impairment risk for all
The Hidden Gem in Novavax's Pipeline You'll Want to Watch
If you've looked into Novavax (NASDAQ: NVAX), you know the clinical-stage biotech's primary focus is on its experimental RSV F vaccine. Novavax has had its fair share of ups and downs with that